$LRMR
Larimar Therapeutics, Inc.

2019 Q1 Form 10-K Financial Statement

#000156459019007863 Filed on March 14, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2017 Q4 2017 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.650M $2.450M $3.120M
YoY Change 11.62% -23.44% -35.4%
% of Gross Profit
Research & Development $9.630M $10.91M $9.723M
YoY Change -22.54% 49.86% -2.78%
% of Gross Profit
Depreciation & Amortization $51.00K $50.00K $50.00K
YoY Change 2.0% -16.67% 0.0%
% of Gross Profit
Operating Expenses $13.28M $13.36M $12.84M
YoY Change -15.44% 27.52% -13.42%
Operating Profit -$13.28M -$12.84M
YoY Change -15.44% -13.42%
Interest Expense $500.0K $270.0K $31.00K
YoY Change 9.17% 575.0% -76.52%
% of Operating Profit
Other Income/Expense, Net $165.0K $255.0K
YoY Change -164.96% 63.46%
Pretax Income -$13.11M -$13.09M -$12.59M
YoY Change -17.86% 25.38% -14.24%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$4.724M -$13.09M -$12.59M
YoY Change -70.39% 25.38% -14.24%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$4.215M -$5.716M -$5.498M
COMMON SHARES
Basic Shares Outstanding 37.32M 27.49M shares 27.48M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2017 Q4 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $104.7M $102.1M $93.18M
YoY Change 17.55% -21.01% -32.8%
Cash & Equivalents $37.76M $40.78M $19.19M
Short-Term Investments $68.20M $61.28M $73.99M
Other Short-Term Assets $1.300M $1.900M $2.000M
YoY Change -7.14% 35.71% 33.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $107.5M $104.9M $95.66M
YoY Change 17.59% -19.84% -32.43%
LONG-TERM ASSETS
Property, Plant & Equipment $1.200M $528.0K $551.0K
YoY Change 150.52% -20.12% -23.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $57.00K $57.00K $57.00K
YoY Change -56.82% -6.56% -32.14%
Total Long-Term Assets $2.685M $585.0K $608.0K
YoY Change 125.25% -18.98% -46.53%
TOTAL ASSETS
Total Short-Term Assets $107.5M $104.9M $95.66M
Total Long-Term Assets $2.685M $585.0K $608.0K
Total Assets $110.2M $105.5M $96.26M
YoY Change 18.97% -19.84% -32.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.156M $3.020M $2.676M
YoY Change -16.86% 17.42% -26.48%
Accrued Expenses $3.300M $4.273M $3.090M
YoY Change -9.86% 14.47% -32.53%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $7.300M $0.00 $1.300M
YoY Change -100.0% -58.06%
Total Short-Term Liabilities $13.73M $7.293M $7.034M
YoY Change 84.1% -26.29% -37.97%
LONG-TERM LIABILITIES
Long-Term Debt $13.50M $20.00M $0.00
YoY Change -33.17% -100.0%
Other Long-Term Liabilities $600.0K
YoY Change
Total Long-Term Liabilities $14.10M $20.00M $0.00
YoY Change -30.2% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.73M $7.293M $7.034M
Total Long-Term Liabilities $14.10M $20.00M $0.00
Total Liabilities $27.80M $27.29M $7.034M
YoY Change 0.66% 175.85% -43.9%
SHAREHOLDERS EQUITY
Retained Earnings -$289.6M -$276.5M
YoY Change 21.9% 21.74%
Common Stock $367.9M $365.8M
YoY Change 2.36% 2.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.224M $78.22M $89.23M
YoY Change
Total Liabilities & Shareholders Equity $110.2M $105.5M $96.26M
YoY Change 18.99% -19.84% -32.55%

Cashflow Statement

Concept 2019 Q1 2017 Q4 2017 Q3
OPERATING ACTIVITIES
Net Income -$4.724M -$13.09M -$12.59M
YoY Change -70.39% 25.38% -14.24%
Depreciation, Depletion And Amortization $51.00K $50.00K $50.00K
YoY Change 2.0% -16.67% 0.0%
Cash From Operating Activities -$12.47M -$9.830M -$12.09M
YoY Change -5.99% 13.38% 9.61%
INVESTING ACTIVITIES
Capital Expenditures $2.000K -$30.00K -$10.00K
YoY Change 100.0%
Acquisitions
YoY Change
Other Investing Activities $810.0K $12.71M $300.0K
YoY Change -95.49% -24.88% -98.18%
Cash From Investing Activities $807.0K $12.69M $280.0K
YoY Change -95.51% -25.0% -98.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 95.00K 18.73M -730.0K
YoY Change -63.6% -2564.47% 25.86%
NET CHANGE
Cash From Operating Activities -12.47M -9.830M -12.09M
Cash From Investing Activities 807.0K 12.69M 280.0K
Cash From Financing Activities 95.00K 18.73M -730.0K
Net Change In Cash -11.57M 21.59M -12.54M
YoY Change -333.53% 188.25% -359.63%
FREE CASH FLOW
Cash From Operating Activities -$12.47M -$9.830M -$12.09M
Capital Expenditures $2.000K -$30.00K -$10.00K
Free Cash Flow -$12.47M -$9.800M -$12.08M
YoY Change -5.98% 13.03% 9.52%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
37315118
CY2018Q2 dei Entity Public Float
EntityPublicFloat
201800000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49331000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40777000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
68735000
CY2017Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
61275000
CY2018Q4 zfgn Tax Incentive Receivable Current
TaxIncentiveReceivableCurrent
1536000
CY2017Q4 zfgn Tax Incentive Receivable Current
TaxIncentiveReceivableCurrent
946000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1728000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1927000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
121330000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
104925000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
375000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
528000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
57000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
57000
CY2018Q4 us-gaap Assets
Assets
121762000
CY2017Q4 us-gaap Assets
Assets
105510000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3590000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3020000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4261000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4273000
CY2018Q4 us-gaap Notes Payable Current
NotesPayableCurrent
5455000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13306000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7293000
CY2017Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
20000000
CY2017Q4 us-gaap Liabilities
Liabilities
27293000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
37000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
27000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
93271000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018 us-gaap Revenues
Revenues
0
CY2017 us-gaap Revenues
Revenues
0
CY2016 us-gaap Revenues
Revenues
0
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40839000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39936000
CY2018Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
15185000
CY2018Q4 us-gaap Liabilities
Liabilities
28491000
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
444212000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
367825000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-350945000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-289577000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-33000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-58000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
78217000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
121762000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
105510000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37287221
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27489457
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37287221
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27489457
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47929000
CY2016 zfgn Increase Decrease In Tax Incentives Receivable
IncreaseDecreaseInTaxIncentivesReceivable
-970000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
569000
CY2016 us-gaap Operating Expenses
OperatingExpenses
58225000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12160000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18289000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-413000
CY2018 zfgn Increase Decrease In Tax Incentives Receivable
IncreaseDecreaseInTaxIncentivesReceivable
666000
CY2017 zfgn Increase Decrease In Tax Incentives Receivable
IncreaseDecreaseInTaxIncentivesReceivable
553000
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27297934
CY2018 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
25000
CY2017 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
22000
CY2016 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
127000
CY2018 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
25000
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
22000
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
127000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-61343000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52006000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
169110000
CY2016 zfgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
220000
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
35000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
8301000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
10113000
CY2017 us-gaap Paid In Kind Interest
PaidInKindInterest
13000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10113000
CY2016 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
127000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
121727000
CY2017 zfgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
195000
CY2017 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
22000
CY2016 us-gaap Paid In Kind Interest
PaidInKindInterest
43000
CY2018 us-gaap Interest Expense
InterestExpense
1898000
CY2018 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-237000
CY2017 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
140000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
971000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-61368000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.90
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.90
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32228721
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27433239
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
64410000
CY2018 zfgn Stock Issued During Period Value Stock Options Exercised And Employee Stock Purchase Plan
StockIssuedDuringPeriodValueStockOptionsExercisedAndEmployeeStockPurchasePlan
2360000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9627000
CY2018 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
25000
CY2018 us-gaap Profit Loss
ProfitLoss
-61368000
CY2017 us-gaap Profit Loss
ProfitLoss
-52028000
CY2016 us-gaap Profit Loss
ProfitLoss
-57878000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
9627000
CY2018 us-gaap Depreciation
Depreciation
261000
CY2016 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-328000
CY2018 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-76000
CY2017 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
46000
CY2016 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-6000
CY2018 zfgn Premium On Marketable Securities
PremiumOnMarketableSecurities
6000
CY2017 zfgn Premium On Marketable Securities
PremiumOnMarketableSecurities
359000
CY2016 zfgn Premium On Marketable Securities
PremiumOnMarketableSecurities
340000
CY2018 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
670000
CY2017 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-246000
CY2016 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-1037000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-199000
CY2016 us-gaap Interest Paid Net
InterestPaidNet
388000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
432000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
448000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4625000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
628000
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
8554000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
8425000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3243000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32352000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35595000
CY2018 zfgn Public Offering Cost Included In Accounts Payable
PublicOfferingCostIncludedInAccountsPayable
138000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
1144000
CY2017 us-gaap Interest Paid Net
InterestPaidNet
141000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
575000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2254000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-51487000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-43784000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-51975000
CY2018 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
110388000
CY2017 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
150213000
CY2016 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
188600000
CY2018 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
117147000
CY2017 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
114511000
CY2016 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
136528000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
108000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
55000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
660000
CY2016 zfgn Deposits For Leased Property
DepositsForLeasedProperty
-35000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6867000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
35647000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
51447000
CY2017 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
20000000
CY2017 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3633000
CY2016 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2935000
CY2018 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2360000
CY2017 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
195000
CY2016 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
220000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
64860000
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
312000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
66908000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16562000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2715000
CY2018 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2005-11-22
zfgn Net Proceeds From Sale Of Securities
NetProceedsFromSaleOfSecurities
397900000
CY2018Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
118100000
CY2018 us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
0
CY2018 zfgn Likelihood Percentage Minimum
LikelihoodPercentageMinimum
0.50
CY2018Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
45210000
CY2018Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
113945000
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities as of the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from the Company&#8217;s estimates. </p>
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk and of Significant Suppliers </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company has all cash, cash equivalents and marketable securities balances at three accredited financial institutions in amounts that exceed federally insured limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.86%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to these programs. These programs could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs. </p>
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
925000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1036000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
550000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
508000
CY2017Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
17349000
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
78624000
CY2018Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2017Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
61333000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8301000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9933000
CY2016 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
200000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
464000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
226000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
0
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
0
CY2017Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
58000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q4 zfgn Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1526000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-58708000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-49954000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-57799000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-2660000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-2074000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-79000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-61368000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-52028000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-57878000
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2018 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.042
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2291000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2229000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
690000
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
400000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
300000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
400000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017Q4 zfgn Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1647000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
221000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
292000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
223000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
105000
CY2017Q4 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
20000000
CY2018Q4 zfgn Line Of Credit Facility Debt Default Minimum Amount
LineOfCreditFacilityDebtDefaultMinimumAmount
300000
CY2018Q4 us-gaap Notes Payable
NotesPayable
20000000
CY2017Q4 us-gaap Notes Payable
NotesPayable
20000000
CY2018Q4 zfgn Long Term Notes Payable Before Accretion
LongTermNotesPayableBeforeAccretion
14545000
CY2017Q4 zfgn Long Term Notes Payable Before Accretion
LongTermNotesPayableBeforeAccretion
20000000
CY2018Q4 us-gaap Debt Instrument Periodic Payment Terms Balloon Payment To Be Paid
DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
640000
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
5455000
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
7273000
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
7272000
CY2018Q4 us-gaap Long Term Debt
LongTermDebt
20000000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9627000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.041
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.029
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.037
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.024
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.039
CY2018 zfgn Effective Income Tax Rate Reconciliation Orphan Drug Tax Credits
EffectiveIncomeTaxRateReconciliationOrphanDrugTaxCredits
0.000
CY2017 zfgn Effective Income Tax Rate Reconciliation Orphan Drug Tax Credits
EffectiveIncomeTaxRateReconciliationOrphanDrugTaxCredits
0.000
CY2016 zfgn Effective Income Tax Rate Reconciliation Orphan Drug Tax Credits
EffectiveIncomeTaxRateReconciliationOrphanDrugTaxCredits
-0.013
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.051
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.015
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.007
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
-0.009
CY2016 zfgn Valuation Allowance Deferred Tax Asset Change In Amount Increase
ValuationAllowanceDeferredTaxAssetChangeInAmountIncrease
23179000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
16600000
CY2017Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
87681000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
97720000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
74541000
CY2018Q4 zfgn Deferred Tax Assets Other Noncurrent
DeferredTaxAssetsOtherNoncurrent
19000
CY2017Q4 zfgn Deferred Tax Assets Other Noncurrent
DeferredTaxAssetsOtherNoncurrent
13000
CY2018Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
101692000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
-0.014
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.000
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.652
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.012
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.013
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.229
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.288
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.401
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2018Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
58832000
CY2017Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
49325000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
16728000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13848000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
19331000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
16759000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements
1918000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements
1646000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4371000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
5568000
CY2018Q4 zfgn Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities Noncurrent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesNoncurrent
493000
CY2017Q4 zfgn Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities Noncurrent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesNoncurrent
522000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
101692000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
87681000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
101692000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
87681000
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2017Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2017 zfgn Valuation Allowance Deferred Tax Asset Change In Amount Decrease
ValuationAllowanceDeferredTaxAssetChangeInAmountDecrease
10039000
CY2018 zfgn Valuation Allowance Deferred Tax Asset Change In Amount Increase
ValuationAllowanceDeferredTaxAssetChangeInAmountIncrease
14011000
CY2018Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14570000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.57
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
12840000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
3400000
CY2018Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018 zfgn Tax Cuts And Jobs Act Of2017 Net Operating Losses Carryforward Maximum Percentage Of Taxable Income
TaxCutsAndJobsActOf2017NetOperatingLossesCarryforwardMaximumPercentageOfTaxableIncome
0.80
CY2017 zfgn Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Deferred Tax Liability Provisional Income Tax Benefit
TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityProvisionalIncomeTaxBenefit
33800000
CY2018 zfgn Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
0
CY2018 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.03
CY2016Q4 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.31
CY2016 us-gaap Restructuring Charges
RestructuringCharges
1400000
CY2016 us-gaap Restructuring Costs
RestructuringCosts
1403000
CY2016Q4 us-gaap Restructuring Reserve
RestructuringReserve
376000
CY2017 us-gaap Restructuring And Related Cost Incurred Cost
RestructuringAndRelatedCostIncurredCost
24000
CY2017 us-gaap Payments For Restructuring
PaymentsForRestructuring
400000
CY2018Q1 us-gaap Revenues
Revenues
0
CY2018Q2 us-gaap Revenues
Revenues
0
CY2018Q3 us-gaap Revenues
Revenues
0
CY2018Q4 us-gaap Revenues
Revenues
0
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
15702000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
15560000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
15169000
CY2018Q4 us-gaap Operating Expenses
OperatingExpenses
14691000
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15956000
CY2018Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15775000
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15067000
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27541594
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27565064
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36619575
CY2018Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37036065
CY2017Q1 us-gaap Revenues
Revenues
0
CY2017Q2 us-gaap Revenues
Revenues
0
CY2017Q3 us-gaap Revenues
Revenues
0
CY2017Q4 us-gaap Revenues
Revenues
0
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
13265000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
13536000
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
13358000
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13011000
CY2017Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13347000
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12585000
CY2017Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13085000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.49
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.46
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.48
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27350673
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27407408
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27483550
CY2017Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27489397

Files In Submission

Name View Source Status
0001564590-19-007863-index-headers.html Edgar Link pending
0001564590-19-007863-index.html Edgar Link pending
0001564590-19-007863.txt Edgar Link pending
0001564590-19-007863-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g5rbolvqdc1v000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
zfgn-10k_20181231.htm Edgar Link pending
zfgn-20181231.xml Edgar Link completed
zfgn-20181231.xsd Edgar Link pending
zfgn-20181231_cal.xml Edgar Link unprocessable
zfgn-20181231_def.xml Edgar Link unprocessable
zfgn-20181231_lab.xml Edgar Link unprocessable
zfgn-20181231_pre.xml Edgar Link unprocessable
zfgn-ex231_11.htm Edgar Link pending
zfgn-ex311_10.htm Edgar Link pending
zfgn-ex312_9.htm Edgar Link pending
zfgn-ex321_8.htm Edgar Link pending